Maeda et al.
Supplementary Table 1 Clinical and Immuno-histochemical Characteristics of DLBCL Patients
POKEMON expression
Variable
Patients – no.
Mean age – yr
Age >60 – no.
Sex – no.
Male
Female
AAb stage – no.
I or II
III or IV
IPIc – no.
Low
Low-Intermediate
High-Intermediate
High
BM involvement – no.
Yes
No
LDHd level – no.
Normal
Eleveted
BCL2 – no.
Positive
Negative
CD10 – no.
Positive
Negative
BCL6 – no.
Positive
Negative
MUM1 – no.
Positive
Negative
GCB phenotypee – no.
Yes
No
Ki67 – no.
Low
High
Nc
Negative
Positive ( Moderate Strong )
130
129
129
129
41
57
21
89
54
34
52
55
20
37
53
14
29
12
53
35
33
18
20
17
15
17
37
29
20
20
17
9
5
9
5
8
16
12
11
8
11
9
6
5
5
3
5
3
6
27
8
56
4
34
4
22
7
22
22
27
17
14
5
13
12
20
36
39
19
23
17
16
13
20
21
55
15
27
6
28
16
21
43
37
23
23
20
14
6
28
31
40
16
26
15
14
18
15
30
44
19
23
11
21
19
13
36
38
24
15
12
23
98
P Valuef
0.18
0.34
0.54
74
0.46
97
0.54
78
0.08
107
0.40
109
0.27
117
0.43
105
0.02
107
0.20
106
0.29
a. Number of cases with complete data
b. Clinical stage according to Ann Arbor classification1,2
c. International Prognostic Index3
d. Lactate dehydrogenase
e. Germinal Center B cell like4
f. Statistical analyses were performed to see the correlation between POKEMON expression and the indicated valuables.
P-value was generated by a chi-square test.
Supplementary Table 2 Clinical and Immuno-histochemical Characteristics of FL Patients
POKEMON expression
Variable
Patients – no.
Mean age – yr
Age >60 – no.
Sex – no.
Male
Female
Gradea – no.
1
2
3
BM involvement – no.
Yes
No
t(14;18)
Yes
No
BCL2 – no.
Positive
Negative
BCL6 – no.
Positive
Negative
CD10 – no.
Positive
Negative
Ki67 – no.
Low
High
Nc
Negative
Positive ( Moderate Strong )
290
256
256
258
42
58
15
248
57
98
143
56
56
105
58
42
22
16
111
109
64
66
47
43
12
16
13
50
86
103
39
57
43
11
29
60
6
32
41
179
26
104
15
75
27
11
166
51
98
30
68
21
30
10
197
48
114
28
83
20
14
26
153
84
74
63
79
21
30
12
162
83
97
45
65
38
38
1
181
59
123
16
58
43
280
P Valueb
0.49
0.49
0.31
258
0.81
255
0.54
285
0.39
277
<0.001
287
0.59
279
0.003
a. Pathological grade was determined according to WHO classification5
b. Statistical analyses were performed to see the correlation between POKEMON expression and the indicated valuables.
P-value was generated by a chi-square test.
References
1.
2.
3.
4.
5.
Benzel, J. E. International conference on leukemia-lymphoma. Ann Arbor, Michigan,
October, 1967. Del Med J 40, 78-81 (1968).
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W. & Tubiana, M. Report of the
Committee on Hodgkin's Disease Staging Classification. Cancer Res 31, 1860-1 (1971).
A predictive model for aggressive non-Hodgkin's lymphoma. The International
Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329, 987-94 (1993).
Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell
lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-82 (2004).
Jaffe ES, H. N., Stein H and Vardiman JW. Pathology and Genetics of Tumours of
Haematopoietic and Lymphoid Tissues ( IARC Press, Lyon, France, 2001).